Fig. 4.
Fig. 4. Schematic representations of karyotypic and qualitative RT-PCR and real-time RT-PCR follow-up of patients with inv(16) AML. / (A) Karyotypic and qualitative RT-PCR follow-up of 21 patients: karyotypic analysis negative (▵) or positive (▴) for inv(16); molecular analysis negative (○) or positive (●) for CBFβ-MYH11. (B) Real-time RT-PCR of 18 patients (patients 1, 10, 18 had insufficient material for analysis): samples taken at diagnosis or at the moment or relapse (●); samples taken at any time during or after treatment before relapse (); samples taken during follow-up when no subsequent relapse was recorded (○). *Samples that fell in the gray zone with CBFβ-MYH11/ABL ratios between 0.12% and 0.25%. Auto-BMT indicates autologous bone marrow transplantation; allo-BMT, allogeneic bone marrow transplantation; and PBSCT, autologous transplantation with peripheral blood stem cells.

Schematic representations of karyotypic and qualitative RT-PCR and real-time RT-PCR follow-up of patients with inv(16) AML.

(A) Karyotypic and qualitative RT-PCR follow-up of 21 patients: karyotypic analysis negative (▵) or positive (▴) for inv(16); molecular analysis negative (○) or positive (●) for CBFβ-MYH11. (B) Real-time RT-PCR of 18 patients (patients 1, 10, 18 had insufficient material for analysis): samples taken at diagnosis or at the moment or relapse (●); samples taken at any time during or after treatment before relapse (); samples taken during follow-up when no subsequent relapse was recorded (○). *Samples that fell in the gray zone with CBFβ-MYH11/ABL ratios between 0.12% and 0.25%. Auto-BMT indicates autologous bone marrow transplantation; allo-BMT, allogeneic bone marrow transplantation; and PBSCT, autologous transplantation with peripheral blood stem cells.

Close Modal

or Create an Account

Close Modal
Close Modal